ABN/ARSN

15 088 417 403

Rule 3.8A

## Appendix 3E

## Daily share buy-back notice (except minimum holding buy-back and selective buy-back)

Information and documents given to ASX become ASX's property and may be made public.

Name of entity

Sigma Pharmaceuticals Limited

[nfo	ormation about buy-back				
[	Type of buy-back	On-market buy-back			
2	Date Appendix 3C was given to ASX	13 September 2012			
	al of all shares/units bought e been received, before, and	-	o which acceptance		
		Before previous day	Previous day		
3	Number of shares/units bought back or if buy-back is an equal access scheme, in relation to which acceptances have been received	45,170,392	869,901		
4	Total consideration paid or payable for the shares/units	\$31,836,109	\$701,923		

		Before p	revious	s day	Previous day
5	If buy-back is an on-market buy-back	Highest \$0.8000	price	paid:	Highest price paid: \$0.8100
		Lawat			Lowest price paid: \$0.8000
		\$0.6250	price	paid:	Highest price allowed under rule 7.33: \$0.8232

## How many shares/units may still be bought back?

90,059

## **Compliance statement**

- 1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

or, for trusts only:

- 1. The trust is in compliance with all requirements of the Corporations Act as modified by Class Order 07/422, and of the trust's constitution, relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

Sign here: Date: 15 May 2013

(Director/Company secretary)

Print name: SUE MORGAN

== == == ==